The purpose of this reflection paper is to provide recommendations for the evaluation of the cardiovascular safety profile of new, non-generic medicinal products that are intended for long-term treatment of cardiovascular and metabolic diseases. It aims to clarify the requirements for these products at the time of marketing authorisation with respect to data needed for the evaluation and quantification of the cardiovascular safety profile.



Posted on the EMA website on 12 June 2015